Waldemar Schreiner1, Sofiya Gavrychenkova1, Wojciech Dudek1, Ralf Joachim Rieker2, Sebastian Lettmaier3, Rainer Fietkau3, Horia Sirbu1. 1. Division of Thoracic Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. 2. Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. 3. Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Abstract
BACKGROUND: Pathologic complete response (pCR) is dominant prognostic factor determining favorable outcome in locally advanced non-small cell lung cancer (NSCLC) after induction therapy (IT). There is no non-operative diagnostics that adequately estimates the pCR. Aim of this retrospective study was to assess the correlation between clinical and pathological factors in patients with pCR. METHODS: Twenty-five patients with pCR after curative lung resection following IT were assessed using univariate and multivariate Cox regression and descriptive analysis. The survival rate was estimated by Kaplan-Meier method. RESULTS: The IT included chemoradiation with median doses of 50.4 Gy (range, 45-59.4 Gy) combined with platinum-based chemotherapy in 23 patients (92%) and induction platinum-based chemotherapy in 2 patients (8%). Clinical tumor stage before IT was IIIA in 21, IIIB in 4 patients. Mean interval between IT and surgery was 8.1±3.0 weeks. Perioperative morbidity and 30-day mortality was 32% and 4%, respectively. There was no significant correlation of pCR and different clinical and pathological factors. The estimated 5-year long-term survival (LTS) and progressive-free survival (PFS) was 57% and 54%, respectively. The median LTS and PFS was not reached. CONCLUSIONS: pCR in patients with locally advanced NSCLC following IT is an independent prognostic factor, without correlation with pathological and clinical factors. Non-operative accurate assessment of pCR is currently impossible. Surgical resection enables secure identification of pCR and might improve the patient stratification for additive therapy.
BACKGROUND: Pathologic complete response (pCR) is dominant prognostic factor determining favorable outcome in locally advanced non-small cell lung cancer (NSCLC) after induction therapy (IT). There is no non-operative diagnostics that adequately estimates the pCR. Aim of this retrospective study was to assess the correlation between clinical and pathological factors in patients with pCR. METHODS: Twenty-five patients with pCR after curative lung resection following IT were assessed using univariate and multivariate Cox regression and descriptive analysis. The survival rate was estimated by Kaplan-Meier method. RESULTS: The IT included chemoradiation with median doses of 50.4 Gy (range, 45-59.4 Gy) combined with platinum-based chemotherapy in 23 patients (92%) and induction platinum-based chemotherapy in 2 patients (8%). Clinical tumor stage before IT was IIIA in 21, IIIB in 4 patients. Mean interval between IT and surgery was 8.1±3.0 weeks. Perioperative morbidity and 30-day mortality was 32% and 4%, respectively. There was no significant correlation of pCR and different clinical and pathological factors. The estimated 5-year long-term survival (LTS) and progressive-free survival (PFS) was 57% and 54%, respectively. The median LTS and PFS was not reached. CONCLUSIONS: pCR in patients with locally advanced NSCLC following IT is an independent prognostic factor, without correlation with pathological and clinical factors. Non-operative accurate assessment of pCR is currently impossible. Surgical resection enables secure identification of pCR and might improve the patient stratification for additive therapy.
Authors: D Shumway; K Corbin; R Salgia; P Hoffman; V Villaflor; R M Malik; D J Haraf; W T Vigneswaren; A Y Shaikh; P P Connell; M K Ferguson; J K Salama Journal: Lung Cancer Date: 2011-06-14 Impact factor: 5.705
Authors: Christoph Pöttgen; Thomas Gauler; Alexander Bellendorf; Maja Guberina; Andreas Bockisch; Nina Schwenzer; Frank Heinzelmann; Sebastian Cordes; Martin H Schuler; Stefan Welter; Georgios Stamatis; Godehard Friedel; Kaid Darwiche; Karl-Heinz Jöckel; Wilfried Eberhardt; Martin Stuschke Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Vishesh Agrawal; Thibaud P Coroller; Ying Hou; Stephanie W Lee; John L Romano; Elizabeth H Baldini; Aileen B Chen; David M Jackman; David Kozono; Scott J Swanson; Jon O Wee; Hugo J W L Aerts; Raymond H Mak Journal: Lung Cancer Date: 2016-10-14 Impact factor: 5.705
Authors: A M Dinaux; R Amri; L G Bordeianou; T S Hong; J Y Wo; L S Blaszkowsky; J N Allen; J E Murphy; H Kunitake; D L Berger Journal: J Gastrointest Surg Date: 2017-04-06 Impact factor: 3.452
Authors: Haipeng Xu; Lin Dong; Zhang Bin; Huo Yansong; Lin Shaofeng; Liu Chang; Chen Chen; Wang Changli Journal: Drug Deliv Date: 2020-12 Impact factor: 6.419